Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HUN47990 is a bisphosphonate (BP) prodrug with antitumor activity. HUN47990 potently inhibits the in vitro growth of a variety of tumor cell lines, especially hematopoietic cell lines, at nanomolar concentrations. HUN47990 inhibited the prenylation of the RAP1A small GTPase signaling protein at concentrations as low as 1-10 nM. HUN47990 slowed the growth of human bladder cancer cells in an immunodeficient mouse model. HUN47990 is significantly more active than zoledronic acid, the most active FDA-approved BP, and a potential anti-cancer therapeutic. HUN47990 was first reported in ChemMedChem. 2016 Dec 16;11(24):2656-2663 (compound 7). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | HUN47990 is a bisphosphonate (BP) prodrug with antitumor activity. HUN47990 potently inhibits the in vitro growth of a variety of tumor cell lines, especially hematopoietic cell lines, at nanomolar concentrations. HUN47990 inhibited the prenylation of the RAP1A small GTPase signaling protein at concentrations as low as 1-10 nM. HUN47990 slowed the growth of human bladder cancer cells in an immunodeficient mouse model. HUN47990 is significantly more active than zoledronic acid, the most active FDA-approved BP, and a potential anti-cancer therapeutic. HUN47990 was first reported in ChemMedChem. 2016 Dec 16;11(24):2656-2663 (compound 7). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming). |
分子量 | 744.72 |
分子式 | C29H50N2O14P2S |
CAS No. | 1950647-99-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HUN47990 1950647-99-0 Inhibitor inhibitor inhibit